• Pharmacology
  • Allergy, Immunology, and ENT
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious Diseases
  • Neurology
  • OB/GYN
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Mental, Behavioral and Development Health
  • Oncology
  • Rheumatology
  • Sexual Health
  • Pain

Higher risk of premenstrual disorders is seen with higher BMI in childhood

Article

A prospective cohort study examines whether higher childhood body mass index (BMI) was linked to a greater risk of premenstrual symptoms in young adulthood compared than children with lower BMIs.

A higher childhood body mass index (BMI) was linked to a significantly greater risk of premenstrual disorders (PMDs) and premenstrual symptoms in young adulthood compared to children with normal BMI, according to a prospective cohort study in JAMA Network Open.

The study also concluded that individuals with high BMI throughout adolescence reported significantly greater premenstrual symptoms in adulthood compared to those who maintained normal BMI throughout adolescence.1

“A few previous studies have shown that adulthood adiposity is positively associated with PMDs,” said first author Donghao Lu, MD, PhD, an assistant professor of epidemiology at Karolinska Institutet in Stockholm, Sweden. “However, in our 2021 study in the journal Human Reproduction,2 we found that in the cohort from the Growing Up Today Study (GUTS), 70% of individuals with PMDs had first symptom onset in adolescence, suggesting that early life factors may contribute importantly to the etiology.”

Lu told Contemporary OB/GYN® that such an association could be attributable to obesity present already in childhood. “But there was no data on the relationship between childhood BMI and risk of PMDs,” he said.

The study comprised 6,524 US female participants from GUTS and was conducted from 1996 to 2013. The mean age of subjects was 26 years, of whom 93.6% were White and 15.4% met the criteria for a PMD.

BMI was estimated via self-reported height and weight through adolescence and converted to BMI for age. Premenstrual symptoms and identified PMDs were determined with a validated scale based on the Calendar of Premenstrual Experiences.

An increase of standard deviation of BMI reported at a mean age of 12.7 years was connected to a 9% increased risk of PMDs.

Associations were particularly pronounced for premenstrual dysphoric disorder and for PMDs with symptom onset prior to age 20 and remained in the absence of psychiatric comorbidities, including depression, anxiety, and disordered eating behaviors.

In addition, individuals with a high BMI throughout adolescence had a higher burden of premenstrual symptoms versus those with normal BMI throughout adolescence.

However, females with a high BMI early in adolescence, followed by a mild decrease thereafter, did not report a higher incidence of premenstrual symptoms.

“These findings are in line with our hypothesis,” Lu said. “Interestingly, our data showed that BMI from the age of 11 to 18 was positively associated with severity of premenstrual symptoms. In contrast, null associations were noted for body shape in early childhood—5 years of age—or middle-childhood BMI—9 and 10 years of age.”

Unfortunately, the awareness of PMDs among health professionals and the public is low. “There has been some improvement in recent years,” Lu said. “Health care providers should be aware of the risk of PMDs in children with greater body mass and educate girls and their parents about premenstrual symptoms.”

Future research is also needed to clarify further how specific ages at exposure relate to risk, according to Lu.

References

1. Lu D, Aleknaviciute J, Kamperman AM, et al. Association between childhood body size and premenstrual disorders in young adulthood. JAMA Netw Open. Published online March 8, 2022. doi:10.1001/jamanetworkopen.2022.1256

2. Lu D, Aleknaviciute J, Bjarnason R, Tamimi RM, et al. Pubertal development and risk of premenstrual disorders in young adulthood. Hum Reprod. 2021;36(2):455-464.

Related Videos
Image Credit: Marcibowers.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.